Current Editions
FDA, up close and personal: A banker’s recalibration
A former agency advisor’s view from inside FDA: What industry often misreads as dysfunction is rooted in caution, independence and process discipline
Guest Commentary
Discovery & Translation
Raising the bar on causal biology — Syncona’s Chris Hollowood
How evolving discovery, and a strategic pivot, are driving Syncona’s investments thesis on gene therapies and elsewhere
Science Spotlight: Making in vivo CAR T less immunogenic
Plus: BACH1 skews neuronal fate in Down syndrome, and optimized prime editors drive large genomic insertions
Finance
Galapagos spinout Coultreon draws $125M to test SIK3 inhibitor: Venture Report
Plus: Pair of European microbiome companies draw rounds; Apuri backs Sigmeta; and more
BioCentury ISSN 1097-7201